Toggle Main Menu Toggle Search

Open Access padlockePrints

Potential Reductions in United States Coronary Heart Disease Mortality by Treating More Patients

Lookup NU author(s): Professor Julia Critchley


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Approximately one half of the recent decline observed in age-adjusted coronary heart disease (CHD) mortality rates can be attributed to the use of modern medical and surgical interventions. In 2000, however, only about 30% to 60% of eligible patients actually received the appropriate treatment. To examine the reduction in CHD mortality potentially achievable by increasing the provision of specific medical and surgical treatment to eligible patients with CHD in the United States, we integrated the data on CHD patient numbers, medical and surgical treatment uptake levels, and treatment effectiveness using a previously validated CHD policy model. We estimated the number of deaths prevented or postponed for 2000 (baseline) and for an alternative scenario (60% of eligible patients). In 2000, the treatment levels in the United States were generally poor; only 30% to 60% of eligible patients received, the appropriate therapy. These treatments resulted in approximately 159,330 fewer deaths. By treating 60% of eligible patients, 297,470 fewer deaths would have been obtained (minimum 118,360; maximum 628,120), representing 134,635 less than in 2000, with approximately 32% from heart failure therapy, 30% from secondary prevention therapy, 19% from acute coronary syndrome treatment, 15% from primary prevention with statins, 0.5% from hypertension treatment, and 1% from coronary bypass surgery for chronic angina. These findings remained stable in the sensitivity analysis. In conclusion, increasing the proportion of eligible patients with CHD who received the appropriate treatment could have achieved approximately 135,000 fewer deaths in 2000, almost doubling the benefit actually achieved. Future strategies should maximize the delivery of appropriate therapies to all eligible patients with CHD and prioritize medical therapies for secondary prevention and heart failure. (C) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:1703-1709)

Publication metadata

Author(s): Capewell S, O'Flaherty M, Ford ES, Critchley JA

Publication type: Article

Publication status: Published

Journal: American Journal of Cardiology

Year: 2009

Volume: 103

Issue: 12

Pages: 1703-1709

ISSN (print): 0002-9149

ISSN (electronic): 1879-1913

Publisher: Excerpta Medica, Inc.


DOI: 10.1016/j.amjcard.2009.02.036


Altmetrics provided by Altmetric


Funder referenceFunder name
G0500920Medical Research Council